Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.40 |
| ▸ | PYGM | P11217 | 2/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28851205 | 1.00 | PYGB (0.40) | PYGBPYGLPYGMFBP1MEN1 | |
| SCHEMBL28279797 | 1.00 | PYGB (0.40) | PYGBPYGLPYGMFBP1MEN1 | |
| SCHEMBL1932762 | 0.95 | ADSS2 (0.35) | PYGBPYGLPYGMFBP1MEN1 | |
| SCHEMBL28991003 | 0.95 | ADSS2 (0.35) | PYGBPYGLPYGMFBP1MEN1 | |
| SCHEMBL23111917 | 0.95 | ADSS2 (0.35) | PYGBPYGLPYGMFBP1MEN1 | |
| Sulfuric Acid SCHEMBL29192736 | 0.94 | PYGB (0.36) | PYGBPYGLPYGMFBP1MEN1 | |
| SCHEMBL8838940 | 0.85 | FBP1 (0.36) | FBP1 | |
| SCHEMBL4312544 | 0.79 | PYGB (0.40) | PYGBPYGLPYGM | |
| SCHEMBL29655015 | 0.79 | PYGB (0.40) | PYGBPYGLPYGMFBP1 | |
| SCHEMBL10385012 | 0.78 | PYGB (0.42) | PYGBPYGLPYGMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694111-B2 | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent | LUTONIX, INC. (US) | 2017-07-04 | — | — | US | claimed |
| US-20160250386-A1 | MEDICAL DEVICE RAPID DRUG RELEASING COATINGS COMPRISING A THERAPEUTIC AGENT AND A CONTRAST AGENT | LUTONIX INC (US) | 2016-09-01 | — | — | US | claimed |
| US-9248220-B2 | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent | LUTONIX, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20150093337-A1 | MEDICAL DEVICE RAPID DRUG RELEASING COATINGS COMPRISING A THERAPEUTIC AGENT AND A CONTRAST AGENT | LUTONIX INC (US) | 2015-04-02 | — | — | US | claimed |
| US-8932561-B2 | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent | LUTONIX, INC. (US) | 2015-01-13 | — | — | US | claimed |
| US-8425459-B2 | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent | LUTONIX, INC. (US) | 2013-04-23 | — | — | US | claimed |
| JP-2010540159-A | — | — | 2010-12-24 | — | — | JP | claimed |
| EP-2073860-A1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | Lutonix, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2009051614-A1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | LUTONIX, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20080255508-A1 | Such as balloon and stents; medical device with overcoating of drug with additive; bioavailability | LUTONIX, INC. | 2008-10-16 | — | — | US | claimed |
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12605342-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4678198-A2 | POLYMER-ENCAPSULATED DRUG PARTICLES | Tonic Medical, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20080255509-A1 | MEDICAL DEVICE RAPID DRUG RELEASING COATINGS COMPRISING OILS, FATTY ACIDS, AND/OR LIPIDS | LUTONIX, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255508-A1 | Such as balloon and stents; medical device with overcoating of drug with additive; bioavailability | LUTONIX, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255510-A1 | Layer containing therapeutic agent, adjuvant and contrast agent ; high speed supplying agent to tissue; adjuvant contains hyfrophilic part and drug affinity part; overcoating exterior surface of medical device | LUTONIX, INC. | 2008-10-16 | — | — | US | disclosed |
| US-7102023-B2 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040220389-A1 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | PYGB 3445/4885PYGL 2617/4885PYGM 1986/4885 |
| US-20040220389-A1 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | FUT5, FUT6, UGCG | PYGB 1862/4885PYGL 1969/4885PYGM 3828/4885 |
| US-12605342-B2 | Polymer-encapsulated drug particles | MUC1, SLC10A2, EGFR | PYGB 3917/4885PYGL 2421/4885PYGM 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.